Guidance & Visibilty

[madrose1]

ACAD added to Nasdaq Biotechnology Index


ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
Business WirePress Release: ACADIA Pharmaceuticals Inc. – 33 minutes ago


RELATED QUOTES
Symbol Price Change
ACAD 14.08 0.81

SAN DIEGO--(BUSINESS WIRE)--

ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it has been selected for addition to the NASDAQ Biotechnology Index (^NBI) effective prior to today’s market open.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. The index is evaluated semi-annually in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.